1. Medtech Insight
  2. >>Leadership

OneCell Diagnostics’ Mohan Uttarwar Discusses Liquid Biopsy Breakthroughs And The Future Of Precision Oncology

Firm Co-Founder Outlines How Science Meets Scale In Second Part Of The Interview

 
• By Shubham Singh

OneCell’s co-founder Uttarwar discusses clinical validation milestones, CLIA certification, and the startup’s strategic roadmap – from hospital partnerships in India to biopharma collaborations in the US.

As the company gears up for its presence at AACR 2025, this part of the discussion provides a revealing look at the intersection of science, startup execution, and the evolving business of cancer diagnostics.
Key Takeaways

· OneCell has received its CLIA certification in the US and is pursuing CAP and FDA 510(k) pathways, aiming to scale its lab-developed tests without delaying commercial traction.

· With partnerships across 20+ hospitals and hundreds of oncologists in India, OneCell is now targeting Southeast Asia and Africa, and building automated systems for broader reach.

· Backed by a globally trained team and strategic investors, the company is balancing deep scientific R&D with scalable operations and strategic biopharma collaborations.

In the second half of the Medtech Insight’s interview, Mohan Uttarwar, co-founder and CEO of OneCell Diagnostics, dive deeper into...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Interviews

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.